List of works by Hagop Kantarjian

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

scientific article

340B Drug Pricing Program Reform-Reply

scientific article published in March 2016

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

scientific article

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

scientific article published on 27 February 2015

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

scientific article published on 21 December 2015

A cancer trial scandal and its regulatory backlash

scientific article published in January 2014

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia

scientific article published on September 2007

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

scientific article published in April 2004

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

scientific article

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

scientific article published on 6 July 2013

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

scientific article

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia ⬇️

scientific article published on August 20, 2010

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

scientific article

A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia

scientific article published on 28 March 2017

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

scientific article

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

scientific article published on 11 January 2019

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

scientific article published on 05 September 2018

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

scientific article

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat

scientific article published on 17 April 2015

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia

scientific article

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

scientific article published in August 2002

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

scientific article

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

scientific article published on 14 June 2017

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes

scientific article

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

scientific article

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

scientific article published in December 2008

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

scientific article

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

scientific article published on 25 July 2016

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

scientific article

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

scientific article published on 18 July 2017

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

scientific article

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities

scientific article

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

scientific article published on 15 November 2018

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

scientific article

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

scientific article published in February 2007

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

scientific article published on 11 June 2015

A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

scientific article published on October 2013

A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry

scientific article

A potential role of ruxolitinib in leukemia

scientific article published on 03 June 2011

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

scientific article

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

scientific article published on 30 August 2005

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

scientific article published on 10 August 2016

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors

scientific article published on 14 October 2018

A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia

scientific article published on June 2012

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

scientific article

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

scientific article

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

scientific article

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

scientific article

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

scientific article published in March 2003

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

scientific article

A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center

scientific article

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

scientific article

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

scientific article published on July 2005

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

scientific article

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

scientific article published on 16 February 2016

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse

scientific article published on 3 June 2008

Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia

scientific article published in February 2003

Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia

scientific article

Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.

scientific article published on 17 February 2005

Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia

scientific article published on 13 February 2003

Accelerated and blastic phases of chronic myelogenous leukemia

scientific article published in June 2004

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

scientific article published on 23 July 2013

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

scientific article published on 24 April 2012

Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

scientific article published on May 2010

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

scientific article published on 8 May 2006

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

scientific article published in April 2008

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

scientific article

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

scientific article published on 18 March 2016

Acute Lymphoblastic Leukemia, Version 2.2015.

scientific article published on October 2015

Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features

scientific article published on June 2015

Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification

scientific article

Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity

scientific article published on 13 March 2012

Acute lymphoblastic leukemia in adolescents and young adults

scientific article published on 22 March 2017

Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates

scientific article published on 21 June 2013

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

scientific article

Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation

scientific article published on 21 June 2014

Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.

scientific article published in May 2010

Acute myeloid leukemia--major progress over four decades and glimpses into the future

scientific article

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

scientific article published on 24 February 2016

Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.

scientific article

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome

scientific article published in January 2010

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

scientific article

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

scientific article published in May 2003

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

scientific article published on 11 October 2018

Adherence to BCR-ABL inhibitors: issues for CML therapy

scientific article published on 24 May 2012

Adult Acute Lymphoblastic Leukemia

scientific article

Adult acute lymphoblastic leukemia: concepts and strategies

scientific article published on March 2010

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

scientific article published on 25 August 2005

Adult acute myeloid leukemia

scientific article

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemot

scientific article published on May 2009

Advanced-phase chronic myeloid leukemia

scientific article

Advances in the biology and therapy of patients with chronic myeloid leukaemia

scientific article published on September 2009

Advances in the therapy of chronic idiopathic myelofibrosis

scientific article published on September 2006

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

scientific article published in December 2003

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

scientific article published on January 2009

Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.

scientific article published in December 2004

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia

scientific article

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study

scientific article

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy

scientific article published on 7 March 2014

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

scientific article

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

scientific article

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy

scientific article published on February 2004

An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia

scientific article published on November 2012

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

scientific article published on 29 September 2016

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

scientific article published on 31 March 2017

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

scientific article published on 26 December 2007

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

scientific article published on 01 April 2019

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

scientific article

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

scientific article published on 5 February 2016

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia

scientific article

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

scientific article

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

scientific article published in October 2003

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

scientific article published on 23 April 2013

Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature.

scientific article published on December 2006

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

scientific article published on October 2010

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities

scientific article published in November 2017

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

scientific article published on 17 January 2017

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

scientific article

Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia

scientific article

Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia

scientific article published on June 2010

Are high drug prices for hematologic malignancies justified? A critical analysis

scientific article published on 23 June 2015

Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

scientific article published on December 2006

Artificial Intelligence, Big Data, and Cancer

scientific article

Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies

scientific article published in October 2004

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

scientific article published on 28 June 2013

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

scientific article published in October 2007

Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome

scientific article published on 14 September 2011

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

scientific article published on 20 March 2018

Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model

scientific article

Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome

scientific article

Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells

scientific article published on 7 July 2006

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

scientific article

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy

scientific article published on 01 February 2011

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

scientific article

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias

scientific article published on 22 September 2008

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors

scientific article published on 31 March 2009

BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.

scientific article published on March 2008

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

scientific article published on 14 August 2014

BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.

scientific article

Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia

scientific article published on December 2010

Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome

scientific article

Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders

scientific article published on May 2004

Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.

scientific article published on March 2008

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

scientific article

Biology and treatment of chronic myelogenous leukemia

scientific article

Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.

scientific article

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

scientific article

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia

scientific article published on 18 October 2019

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

scientific article published on 3 May 2016

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

scientific article published on March 2017

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

scientific article

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

scientific article published in October 2002

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

scientific article published on 23 January 2013

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

scientific article

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor

scientific article published on 21 April 2011

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

scientific article

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

scientific article published on 27 February 2012

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

scientific article published on 17 December 2013

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

scientific article

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment

scientific article published on 22 August 2019

Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

scientific article

C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome

scientific article published in April 2004

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

scientific article published on November 29, 2010

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

scientific article

CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias

scientific article

CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

scholarly article by Evgeniya Angelova et al published 25 October 2018 in Haematologica

CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count

scientific article published on 4 January 2016

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

scientific article

CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha

scientific article

CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia

scientific article

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

scientific article published on January 2008

Cancer Drugs: An International Comparison of Postlicensing Price Inflation

scientific article published on 7 February 2017

Cancer Genomics in Clinical Context

scientific article

Cancer research in the United States: A critical review of current status and proposal for alternative models

scientific article published on 14 May 2018

Cancer research in the United States: dying by a thousand paper cuts

scientific article published on 6 June 2013

Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia

scientific article

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

scientific article

Cause of death in patients with lower-risk myelodysplastic syndrome

scientific article published on May 2010

Cellular signalling pathways: new targets in leukaemia therapy

scientific article

Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies

scientific article

Central nervous system relapse in adults with acute lymphoblastic leukemia

scientific article published on February 2002

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein

scientific article published on April 2004

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

scientific article published on 20 February 2018

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

scientific article

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

scientific article

Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia

scientific article

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

scientific article

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

scientific article published on October 2012

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

scientific article

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

scientific article

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

scientific article published on 17 February 2009

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia

scientific article published on 24 December 2014

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

scientific article published on 28 October 2008

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

scientific article published on 22 February 2019

Characteristics of pericardial effusions in patients with leukemia

scientific article published on May 2010

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

scientific article

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

scientific article

Chemical and clinical development of darinaparsin, a novel organic arsenic derivative

scientific article published on December 2008

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

scientific article

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

scientific article

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

scientific article

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

scientific article

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

scientific article published on 11 October 2018

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

scientific article

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

scientific article published in November 2003

Chromosome 5q deletion is extremely rare in patients with myelofibrosis

scientific article published on 4 February 2013

Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.

scientific article

Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy

scientific article

Chronic myelogenous leukemia: a review and update of therapeutic strategies

scientific article

Chronic myelogenous leukemia: update on biology and treatment

scientific article

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

scientific article published on 16 June 2009

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

scientific article published on 20 October 2016

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

scientific article published on October 2010

Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature

scientific article published on June 2004

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?

scientific article published on September 2010

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management

scientific article

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

scientific article published on May 2014

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

scientific article published on February 2016

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

scientific article published in March 2018

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

scientific article published on 02 April 2020

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

scientific article

Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment

scientific article

Chronic myeloid leukemia: mechanisms of resistance and treatment

scientific article published on 19 October 2011

Chronic myeloid leukemia: overview of new agents and comparative analysis

scientific article published on June 2013

Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia

scientific article

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease

scientific article published on 01 December 2003

Circulating CD33 and its clinical value in acute leukemia

scientific article published on April 2010

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

scientific article published on 6 November 2009

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

scientific article

Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia

scientific article published on 12 August 2009

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

scientific article

Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies

scientific article

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

scientific article published on 27 April 2018

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

scientific article published in October 2017

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

scientific article published on 26 July 2017

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

scientific article published on 06 November 2020

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

scientific article published on 29 August 2017

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

scientific article published on 18 December 2015

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action

scientific article

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

scientific article published on November 2013

Clinical activity of tipifarnib in hematologic malignancies

scientific article published on March 2007

Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective

scientific article published in June 2010

Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia

scientific article published on 28 July 2016

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

scientific article

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

scientific article

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

scientific article published on 29 October 2020

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

scientific article

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens

scientific article published on 24 June 2017

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

scientific article published on 29 July 2013

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).

scientific article published on 11 October 2016

Clinical correlation of circulating heat shock protein 70 in acute leukemia

scientific article

Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome

scientific article

Clinical effect of point mutations in myelodysplastic syndromes

scientific article

Clinical experience with decitabine in North American patients with myelodysplastic syndrome

scientific article published in December 2005

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

scientific article

Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

scientific article

Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.

scientific article

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

scientific article

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 09 February 2016

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

scientific article

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

scientific article

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

scientific article

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

scientific article published on 20 March 2006

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

scientific article published in Nature Communications

Clinical significance of microcytosis in patients with primary myelofibrosis

scientific article

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

scientific article published on 5 August 2016

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

scientific article published on 24 November 2015

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

scientific article published on 10 January 2006

Clofarabine combinations as acute myeloid leukemia salvage therapy

scientific article published on October 2008

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

scientific article

Clofarabine for the treatment of acute lymphoblastic leukemia

scientific article published on February 2007

Clofarabine in adult acute leukemias: clinical success and pharmacokinetics

scientific article published in October 2004

Clofarabine in leukemia

scientific article

Clofarabine in the treatment of myelodysplastic syndromes

scientific article published on February 2014

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

scientific article

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

scientific article published on 26 January 2012

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

scientific article published on 18 August 2011

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia ⬇️

scientific article published on October 9, 2003

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

scientific article

Clofarabine: emerging role in leukemias

scientific article

Clofarabine: past, present, and future

scientific article

Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations

scientific article published on 17 August 2020

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

scientific article published on 23 August 2017

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

scientific article

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

scientific article published on 20 May 2016

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

scientific article published on July 2015

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

scientific article published on 21 October 2020

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

scientific article published on 12 March 2019

Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients

scientific article published on 31 August 2017

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system

scientific article published on 25 April 2011

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

scientific article published on 29 September 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

scientific article published on September 2016

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

scientific article published on 30 November 2016

Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".

scientific article published in November 2003

Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.

scientific article

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

scientific article

Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen

scientific article published in January 2002

Competing cell clones in myeloproliferative neoplasm

scientific article published on December 2010

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

scientific article

Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.

scientific article

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis

scientific article published on 20 June 2016

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

scientific article published on 20 July 2015

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

scientific article published in April 2009

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

scientific article

Comprehensive craniospinal radiation for controlling central nervous system leukemia

scientific article published on December 2014

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

scientific article published on 24 May 2012

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

scientific article

Congestive heart failure is a rare event in patients receiving imatinib therapy

scientific article

Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

scientific article published on 21 March 2011

Contract research organizations in oncology clinical research: Challenges and opportunities

scientific article

Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS) ⬇️

scientific article published on May 8, 2003

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

scientific article

Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation

scientific article

Current and emerging treatment options in chronic myeloid leukemia

scientific article

Current and future management options for myelodysplastic syndromes

scientific article published on July 2010

Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.

scientific article published in July 2003

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

scientific article

Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults

scientific article published on 3 October 2017

Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment

scientific article

Current therapy of chronic myelogenous leukemia.

scientific article

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

scientific article

Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation

scientific article

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

scientific article

Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease

scientific article published on 20 June 2011

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

scientific article published on 17 August 2016

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis

scientific article

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease

scientific article published on 07 May 2019

DNA methylation in haematological malignancies: the role of decitabine

scientific article published on December 2003

DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia

scientific article published in July 2002

DNA methylation patterns at relapse in adult acute lymphocytic leukemia

scientific article published in June 2002

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

scientific article

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia

scientific article

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

scientific article

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias

scientific article published on May 2007

Dasatinib for the treatment of chronic myeloid leukemia

scientific article

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

scientific article (publication date: 15 June 2006)

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

scientific article published on 19 May 2016

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

scientific article

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 5 June 2010

Decitabine and its role in the treatment of hematopoietic malignancies

scientific article published on August 2007

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

scientific article

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts

scientific article published on 28 May 2015

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

scientific article

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

scientific article published on 8 February 2018

Decitabine in older adults with acute myeloid leukemia: why was the dream broken?

scientific article published in April 2013

Decitabine in the treatment of myelodysplastic syndromes.

scientific article

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration ⬇️

scientific article published on August 24, 2010

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

scientific article published on 15 April 2009

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

scientific article published on 19 January 2016

Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia

scientific article

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

scientific article published on 19 October 2015

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

scientific article published on 08 July 2013

Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis

scientific article published on 27 May 2012

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

scientific article published in January 2009

Development and targeted use of nilotinib in chronic myeloid leukemia.

scientific article

Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

scientific article

Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.

scientific article published on October 2015

Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns

scientific article published on April 2007

Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis

scientific article published on July 2017

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study

scientific article published on 10 June 2013

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

scientific article published on 7 September 2016

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

scientific article published on 06 September 2018

Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia

scientific article published on 29 August 2012

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up

scientific article

Discontinuation of imatinib therapy after achieving a molecular response

scientific article published in October 2004

Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers

scientific article published on 13 November 2013

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

scientific article published on 22 November 2016

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

scientific article published on 12 September 2002

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

scientific article published on 6 December 2017

Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression

scientific article

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion

scientific article published on 24 June 2015

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

scientific article published on 28 September 2009

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

scientific article

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

scientific article published on 8 June 2011

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

scientific article

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

scientific article published on 15 August 2006

Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy

scientific article published on 22 May 2019

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

scientific article published on 08 January 2016

Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications

scientific article published on 19 May 2011

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

scientific article

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

scientific article

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

scientific article published on 25 April 2013

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

scientific article

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

scientific article

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

scientific article published on 21 November 2016

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

scientific article

Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.

scientific article published on 3 July 2003

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

scientific article

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial

scientific article

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study

scientific article published on 22 September 2013

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

scientific article published on 15 December 2008

Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies

scientific article published on 05 October 2014

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

scientific article published on 23 June 2006

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

scientific article published on 17 June 2017

Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia

scientific article published in February 2012

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in September 2003

Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling

scientific article

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

scientific article

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

scientific article published on 01 May 2019

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

scientific article

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

scientific article published on 10 September 2019

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

scientific article published on 3 December 2009

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

scientific article published in July 2003

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

scientific article published on February 2009

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

scientific article published on 20 February 2003

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia

scientific article published on 24 November 2020

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

scientific article published on 31 October 2002

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

scientific article published on 08 November 2018

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

scientific article

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

scientific article

Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

scientific article

Emerging drugs for acute lymphocytic leukemia

scientific article published on 20 December 2013

Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors

scientific article published on March 2007

Emerging therapy for the treatment of acute lymphoblastic leukemia

scientific article published on March 2010

Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.

scientific article published in June 2003

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

scientific article published on 6 June 2017

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia

scientific article published in March 2008

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

scientific article published on 15 October 2012

Epigenetics of acute lymphocytic leukemia

scientific article published on January 2009

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial

scientific article published on 12 July 2011

Eradication of minimal residual disease in hairy cell leukemia

scientific article

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

scholarly article published in Cancer

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

scientific article

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

scientific article published on 02 August 2007

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

scientific article published on 28 July 2015

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

scientific article published on 31 January 2012

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

scientific article published on 26 June 2013

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial

scientific article

Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies

scientific article

Evolution of therapies for chronic myelogenous leukemia

scientific article

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

scientific article

Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy

scientific article

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

scientific article published on 09 January 2003

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

scientific article

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

scientific article

Experimental therapeutics for patients with myeloproliferative neoplasias

scientific article published on 04 October 2010

Experimental therapy in myelofibrosis with myeloid metaplasia

scientific article published on December 2006

Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML

scientific article

Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia

scientific article published on February 2004

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

scientific article published in September 2004

FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

scientific article

FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

scientific article

FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype

scientific article

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

scientific article published on 27 May 2017

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

scientific article published on 4 November 2015

Failure of hypomethylating agent-based therapy in myelodysplastic syndromes

scientific article published on October 2011

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

scientific article

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

scientific article published on 20 May 2008

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

scientific article published on 28 August 2003

Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies

scientific article

Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

scientific article published in January 2002

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

scientific article published on 11 October 2007

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin

scientific article

Feasibility of therapy with hypomethylating agents in patients with renal insufficiency

scientific article

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

scientific article published on 23 May 2016

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

scientific article published on 13 January 2015

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on 14 February 2015

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

scientific article

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

scientific article published on 16 April 2018

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

scientific article published on 14 May 2016

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

scientific article published on 24 February 2012

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

scientific article

First-line therapy for chronic myeloid leukemia: Past, present, and future

scientific article published on May 2009

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

scientific article published in June 2004

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

scientific article

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

scientific article published on 22 October 2015

Flying under the radar: the new wave of BCR-ABL inhibitors

scientific article published on October 2007

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

scientific article published in April 2003

Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.

scientific article published in January 2005

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

scientific article published on 10 January 2011

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

scientific article published on 11 October 2011

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

scientific article published on 12 May 2016

Frontline treatment of acute myeloid leukemia in adults

scientific article published on 11 December 2016

Functional proteomic profiling of AML predicts response and survival

scientific article

Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies

scientific article

GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis

scientific article published on 04 December 2020

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

scientific article published on 21 July 2014

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

scientific article published in June 2002

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

scientific article

Gemtuzumab ozogamicin: time to resurrect?

scientific article

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

scientific article published in March 2003

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

scientific article

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

scientific article

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

scientific article

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

scientific article

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

scientific article published on 01 February 2020

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

scientific article

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia

scientific article published on 27 March 2003

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

scientific article published on 03 May 2019

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

scientific article published on 24 August 2017

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

scientific article published on 22 October 2013

HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target

scientific article published on 24 November 2006

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

scientific article published on 21 October 2019

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

scientific article

Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs

scientific article published on 2 July 2015

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

scientific article published in February 2002

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

scientific article

Hemophagocytic lymphohistiocytosis in adults: An under recognized entity

scientific article published on 20 December 2016

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

scientific article

Hepatitis C: When high drug prices preclude patient benefit

scientific article published on 27 February 2018

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults

scientific article published on 21 November 2016

High cancer drug prices in the United States: reasons and proposed solutions

scientific article published on 6 May 2014

High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome

scientific article published on 30 March 2015

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

scientific article published on 31 August 2009

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

scientific article published on 24 December 2003

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia

scientific article

High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia

scientific article published on 28 June 2017

High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics

article by Maurizio Pellegrino et al published September 2018 in Genome Research

Higher detection rate of JAK2 mutation using plasma.

scientific article

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

scientific article published on 9 November 2017

Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.

scientific article published in September 2006

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

scientific article

Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval

scientific article published on 20 June 2013

Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.

scientific article

How I treat newly diagnosed chronic phase CML

scientific article published on 21 May 2012

How much of US health care spending provides direct care or benefit to patients?

scientific article published on 29 January 2019

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

scientific article

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

scientific article published in August 2016

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

scientific article published on 01 July 2020

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia

scientific article

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

scientific article published on 4 November 2011

Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia

scientific article published on 13 November 2015

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

scientific article published on 07 August 2019

Imatinib and beyond--exploring the full potential of targeted therapy for CML.

scientific article published on 04 August 2009

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

scientific article

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

scientific article

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status

scientific article published on 14 November 2008

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

scientific article published in March 2002

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

scientific article published in May 2002

Imatinib mesylate causes hypopigmentation in the skin

scientific article published in December 2003

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

scientific article

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

scientific article

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

scientific article published on January 2004

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

scientific article

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

scientific article

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

scientific article

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

scientific article published on 29 August 2002

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

scientific article published on 30 November 2004

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

scientific article published in July 2004

Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.

scientific article published in November 2013

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors

scientific article published in March 2007

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

scientific article

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors

scientific article published on 4 December 2017

Immunotherapy based approaches in myelofibrosis

scientific article published on 11 August 2017

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

scientific article published on 4 January 2016

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

scientific article published on 30 April 2020

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia

scientific article published on 03 June 2020

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 11 January 2017

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

scientific article

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

scientific article

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

scientific article published on 3 January 2018

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

scientific article published on 19 November 2019

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

scientific article published on 11 July 2011

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

scientific article

Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy

scientific article published on October 2009

Important therapeutic targets in chronic myelogenous leukemia

scientific article published on February 2007

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

scientific article published on 6 January 2012

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

scientific article

Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience

scientific article

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

scientific article published on 06 April 2018

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines

scientific article published on 26 March 2003

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

scientific article

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience

scientific article

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

scientific article published on 04 March 2019

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

scientific article published on 3 November 2014

Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome

scientific article published in May 2003

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities

scientific article published on 2 February 2015

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

scientific article published in March 2003

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia

scientific article

Infections in patients with aplastic anemia: experience at a tertiary care cancer center.

scientific article

Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells

scientific article published on May 2008

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia

scientific article published on 02 September 2013

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini

scientific article published on 29 October 2012

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

scientific article published on 12 June 2016

Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas

scientific article published on April 2015

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl

scientific article published on 15 April 2019

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

scientific article published on 15 January 2018

Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia

scientific article published on January 2014

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study

scientific article published on 28 March 2019

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

scientific article published on 21 February 2012

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.

scientific article published in May 2015

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

scientific article published in Nature Communications

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

scientific article published on 28 July 2010

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

scientific article published on 29 April 2019

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study

scientific article

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

scientific article

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

scientific article published on 01 June 2005

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

scientific article

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia

scientific article

Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia

scientific article

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

scientific article

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

scientific article

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

scientific article

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

scientific article published in February 2004

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

scientific article

Investigational strategies in chronic myelogenous leukemia

scientific article published in June 2004

Is there a standard induction regimen for patients with AML?

scientific article

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms ⬇️

scientific article (publication date: 13 August 2010)

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

scientific article

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

scientific article

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

scientific article published on 27 February 2019

Janus kinase 2: a critical target in chronic myelogenous leukemia

scientific article published on July 2006

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

scientific article published on February 2011

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

scientific article published on 6 June 2015

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients

scientific article published on 19 October 2016

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

scientific article

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

scientific article

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

scientific article published on 2 June 2008

Kit inhibitor APcK110 extends survival in an AML xenograft mouse model

scientific article

Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells

scientific article published on 21 April 2009

L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia.

scientific article published on 26 February 2018

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

scientific article published on 4 February 2014

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

scholarly article by Musa Yilmaz et al published 16 January 2019 in Blood Cancer Journal

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

scientific article

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

scientific article

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

scientific article

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

scientific article

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

scientific article published on 26 January 2017

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

scientific article published on 10 May 2021

Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.

scientific article published on February 2011

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

scientific article published on 3 October 2017

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

scientific article published on 14 March 2018

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

scientific article published on January 2003

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

scientific article published on March 2017

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

scientific article

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

scientific article

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

scientific article published on 15 June 2016

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

scientific article published on 15 March 2018

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

scientific article published on June 2015

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

scholarly article by Oliver Ottmann et al published 3 September 2018 in Blood Cancer Journal

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

scientific article

Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement

scientific article published in March 2008

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

scientific article published in March 2003

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes

scientific article

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 25 September 2019

Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody

scientific article published on November 2012

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

scientific article published in March 2006

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr

scientific article

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

scientific article published on 21 December 2016

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

scientific article

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

scientific article published on 25 February 2014

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

scientific article

Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors

scientific article published on 13 October 2010

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

scientific article

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

scientific article published on 07 January 2021

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

scientific article published on 26 October 2017

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

scientific article

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

scientific article

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

scientific article published on 30 January 2020

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

scientific article published on 23 June 2016

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

scientific article

Long-term results of frontline dasatinib in chronic myeloid leukemia

scientific article published on 30 January 2020

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

scientific article published on 14 April 2008

Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial

scientific article

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

scientific article

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

scientific article published on 03 November 2020

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

scientific article

Low frequency of H3.3 mutations and upregulated DAXX expression in MDS.

scientific article

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

scientific article

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

scholarly article by George Z Rassidakis et al published 19 October 2018 in Blood Cancer Journal

MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells

scientific article

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

scientific article

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells

scientific article published on 04 July 2016

MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy

scientific article published on 16 July 2013

MYC protein expression is an important prognostic factor in acute myeloid leukemia

scientific article published on 09 May 2018

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

scientific article published on 16 August 2011

Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

scientific article published on 31 May 2016

Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments

scientific article published on February 2017

Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience

scientific article published on 07 December 2020

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

scientific article published on 17 December 2013

Management of imatinib-resistant patients with chronic myeloid leukemia

scientific article published on April 2013

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

scientific article published on March 2007

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

scientific article published in November 2004

Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy

scientific article published on 13 April 2009

Market spiral pricing of cancer drugs.

scientific article

Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction.

scientific article published in January 2002

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome

scientific article published on 01 June 2017

Mature T-cell leukemias

scientific article

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

scientific article (publication date: August 2013)

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

scientific article

Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment

scientific article published on 2 October 2012

Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations

scientific article published in April 2009

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

scientific article

Meir Wetzler, MD.

scientific article published in April 2015

Mesenchymal Stem Cells Differentiate into Osteoblasts in the Presence of AML Cells through Up-regulation of RUNX2 and Induce Chemo-resistance

article by V. Lokesh Battula et al published June 2015 in Clinical Lymphoma, Myeloma & Leukemia

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

scientific article

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

scientific article

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

scientific article published on 22 October 2015

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

scientific article published on 11 May 2017

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

scientific article published in April 2003

Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias

scientific article

Modern treatment programs for adults with acute lymphoblastic leukemia

scientific article published on July 2007

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

scientific article

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a

scientific article published on 19 June 2013

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

scientific article

Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia

scientific article published on 09 July 2012

Molecular differences between small and large cells in patients with chronic lymphocytic leukemia

scientific article

Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications

scientific article published on May 2008

Molecular resistance: an early indicator for treatment change?

scientific article published on 28 January 2012

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

scientific article

Monitoring molecular response in chronic myeloid leukemia ⬇️

scientific article published on October 19, 2010

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

scientific article

Monoclonal antibody therapy for hairy cell leukemia

scientific article published on October 2006

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia

scientific article published on October 2009

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

scientific article

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

scientific article

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

scientific article published on 15 June 2009

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

scientific article

Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase

scientific article published on 5 March 2013

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

scientific article published on 03 October 2011

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogene

scientific article published on 06 February 2014

Mutant BCR-ABL clones in chronic myeloid leukemia

scientific article published on March 2011

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

scientific article

Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line

scientific article published on November 2002

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias

scientific article published on 12 December 2008

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable

scientific article published on 21 September 2018

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

scientific article

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

scientific article published on 29 June 2006

Myelodysplastic syndromes: the complexity of stem-cell diseases

scientific article published on February 2007

Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

scientific article

Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia

scientific article published on September 2008

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

scientific article

Myelopathy following intrathecal chemotherapy in adults: a single institution experience

scientific article

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

scientific article

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

scientific article published on 9 September 2003

N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).

scientific article published on March 2003

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.

scientific article

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

scientific article

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia

scientific article published on 18 March 2019

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

scientific article published on 04 September 2020

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

scientific article published on 26 May 2017

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

scientific article published on 5 January 2007

Neutrophilic-chronic myeloid leukemia

Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course

scientific article

New Series: SOHO 'State of the Art Updates and Next Questions'.

scientific article

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

scientific article published on 4 July 2017

New agents in acute myeloid leukemia and other myeloid disorders

scientific article published on February 2004

New agents in the treatment of acute lymphocytic leukaemia

scientific article

New approaches in the treatment of myelofibrosis

scientific article

New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia

scientific article published on July 2007

New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

scientific article published on February 2011

New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

scientific article published on 17 April 2015

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

scientific article published on December 2006

New nucleoside analogues in clinical development

scientific article published on January 1, 2002

New strategies in chronic myeloid leukemia

scientific article

New targeted approaches in chronic myeloid leukemia

scientific article

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

scientific article published on January 2007

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

scientific article published on 18 October 2013

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

scientific article

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

scientific article

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

scientific article

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia ⬇️

scientific article published on November 13, 2010

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review ⬇️

scientific article published on June 15, 2010

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

scientific article (publication date: 15 June 2006)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

scientific article

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

scientific article published on 15 March 2013

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

scientific article published on 22 November 2010

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

article

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

scientific article

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

scientific article published on 17 August 2011

Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

scientific article published on January 2009

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

scientific article published on 8 February 2018

Novel approaches in the treatment of systemic mastocytosis

scientific article published on October 2006

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

scientific article

Novel therapies for myelodysplastic syndromes

scientific article published in July 2004

Novel therapies for patients with chronic myeloid leukemia

scientific article published on April 2004

Novel therapies for relapsed acute lymphoblastic leukemia

scientific article

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity

scientific article published on 01 July 2007

Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

scientific article published on November 2006

Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia

scientific article published on 23 July 2013

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

scientific article published on 10 June 2013

Oncogenic signals as treatment targets in classic myeloproliferative neoplasms

scientific article published on January 2009

Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?

scientific article published on May 2007

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management

scientific article published on 03 December 2019

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

scientific article published on March 2010

Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?

scientific article published on November 2006

Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules

scientific article published on March 2008

Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML

scientific article published on 13 April 2020

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

scientific article published on 26 April 2010

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

scientific article

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma

scientific article published on 29 December 2008

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

scientific article published on 14 June 2013

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

scientific article

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

scientific article published on December 2008

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

scientific article published on 18 January 2010

Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

scientific article published on 05 June 2020

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

scientific article published on 29 October 2009

Outcome of patients with acute myelogenous leukemia after second salvage therapy

scientific article published on August 2005

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

scientific article

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

scientific article

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

scientific article published on August 2010

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

scientific article published on 27 November 2017

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

scientific article

Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure

scientific article published on 28 April 2011

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

scientific article

Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation

scientific article

Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia

scientific article published on 25 September 2017

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

scientific article published on 15 March 2017

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

scientific article published on 8 January 2015

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

scientific article published on 24 May 2019

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

scientific article published on 22 December 2015

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

scientific article published on April 2014

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

scientific article published on 17 January 2018

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

scientific article published on 08 October 2020

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

scientific article published on 24 October 2011

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation

scientific article published on 7 April 2017

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival

scientific article published on 23 September 2018

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

scientific article published on 01 November 2007

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

scientific article published on 5 January 2016

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

scientific article published on 31 March 2012

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms

scientific article published on 15 November 2017

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

scientific article

Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.

scientific article published on 6 March 2018

Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome

scientific article published on 14 August 2013

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

scientific article

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

scientific article

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

scientific article

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

scientific article published on 13 October 2009

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders

scientific article published on June 2006

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of a

scientific article published in June 1995

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

scientific article published on 30 July 2016

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

scientific article published on 09 May 2011

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

scientific article published on 22 September 2016

Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia

scholarly article by Chi Young Ok et al published February 2019 in Haematologica

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

scientific article published on 5 December 2016

Pharmacokinetic evaluation of decitabine for the treatment of leukemia

scientific article published on May 2011

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

scientific article published in December 2003

Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia

scientific article

Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

scientific article

Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

scientific article published on 22 July 2020

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

scientific article

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

scientific article published on 2 May 2015

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

scientific article

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

scientific article published on December 2009

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

scientific article published on 01 September 2005

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

scientific article

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

scientific article published on 8 August 2012

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

scientific article published on 6 November 2003

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

scientific article

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

scientific article

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia

scientific article published on 22 January 2019

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

scientific article published in August 2006

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

scientific article

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

scientific article published on 14 March 2020

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

scientific article

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

scientific article

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

scientific article published on 29 June 2011

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

scientific article

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

scientific article published on 23 April 2013

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

scientific article

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

scientific article published on 14 October 2016

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

scientific article

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

scientific article

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

scientific article published on 15 March 2012

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

scientific article published on 3 May 2018

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

scientific article

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

scientific article published on 17 January 2017

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

scholarly article by Farhad Ravandi et al published November 2018 in Haematologica

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

scientific article published on 15 April 2009

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

scientific article

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

scientific article published in December 2003

Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia

scientific article published in July 2002

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

scientific article published in April 2004

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

scientific article published on 23 November 2009

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

scientific article published in March 2003

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

scientific article

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

scientific article published on 11 December 2013

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia

scientific article

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

scientific article

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

scientific article published on 10 June 2013

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

scientific article

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

scientific article published on 19 February 2015

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

scientific article

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

scientific article

Phase I study of bortezomib in refractory or relapsed acute leukemias

scientific article published in May 2004

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

scientific article published on November 2005

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia

scientific article published on 11 May 2016

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

scientific article published on 16 May 2011

Phase I study of oral topotecan in hematological malignancies ⬇️

scientific article published on September 15, 2003

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

scientific article published on 03 September 2013

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

scientific article published on 14 September 2018

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

scientific article

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

scientific article published on 02 August 2016

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome

scientific article

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

scientific article

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

scientific article published in January 2008

Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia

scientific article published on 18 July 2020

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

scientific article

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.

scientific article

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

scientific article published in January 2007

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

scientific article

Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia

scientific article published on 10 June 2013

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

scientific article

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

scientific article published on 17 February 2015

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

scientific article published in April 2004

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma

scientific article

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

scientific article published in April 2003

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

scientific article

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

scientific article published on 21 December 2009

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

scientific article published on June 2008

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

scientific article

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

scientific article

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

scientific article published on March 2007

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

scientific article published on 9 May 2005

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

scientific article published on 19 November 2014

Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis

scientific article

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

scientific article

Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

scientific article

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

scientific article

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

scientific article published in February 2002

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

scientific article published in December 2003

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

scientific article published on 16 June 2020

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

scientific article published on 9 February 2017

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

scientific article published on March 2014

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

scientific article published on 4 September 2015

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

scientific article published on 14 May 2012

Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

scientific article

Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in Combination With Standard Chemotherapy in Patients With AML or High-Risk MDS.

scientific article published on 20 February 2018

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia

scientific article published on 28 July 2019

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

scientific article published on 21 October 2019

Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.

scientific article published in March 2018

Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives

scientific article published on June 2002

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

scientific article (publication date: 20 May 2003)

Philadelphia-positive acute lymphoblastic leukemia: current treatment options

scientific article published on October 2012

Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia

scientific article published on 31 March 2011

Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy

scientific article published on 27 September 2007

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

scientific article

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase

scientific article published on August 2011

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

scientific article

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

scientific article

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

scientific article

Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes

scientific article published on 12 September 2014

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

scientific article published on 20 July 2006

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.

scientific article

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

article

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

scientific article

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

scientific article published on 22 March 2018

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

scientific article published on 21 May 2013

Ponatinib in refractory Philadelphia chromosome-positive leukemias

scientific article

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

scientific article

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

scientific article published on 22 December 2016

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

scientific article published on 30 December 2011

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

scientific article published on 8 January 2015

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

scientific article published on 03 March 2020

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

article

Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid

scientific article published in February 2005

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

scientific article

Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia

scientific article

Potential role of sorafenib in the treatment of acute myeloid leukemia

scientific article published on December 2008

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

scientific article

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

scientific article published on 12 June 2014

Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia

scientific article published on March 2008

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia

scientific article published on 28 February 2014

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

scientific article published on 7 April 2010

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

scientific article

Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?

scientific article

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

scientific article

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system

scientific article

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

scientific article published on 20 December 2017

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

scientific article

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

scientific article published on 3 October 2011

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in May 2003

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

scientific article

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

scientific article

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

scientific article

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

scientific article published on 30 January 2006

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

scientific article published on 02 December 2016

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

scientific article published on 8 January 2007

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology

scientific article published in August 2016

Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia

scientific article published on December 2010

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R

scientific article published on 26 September 2018

Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System

scientific article published in June 2007

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

scientific article (publication date: February 2002)

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

scientific article published on 25 July 2017

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

scientific article

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

scientific article

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

scientific article published on 5 April 2013

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

scientific article

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

scientific article

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

scientific article published on 21 January 2016

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

scientific article published on 3 October 2016

Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis

scientific article published on 21 February 2013

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

scientific article

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin

scientific article published on 17 January 2019

Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia

scientific article published on 04 February 2013

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

scientific article

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

scientific article

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

scientific article

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

scientific article

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

scientific article published on 24 June 2019

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

scientific article

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

scientific article

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

scientific article published on 09 September 2018

Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors

scientific article

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

scientific article published on 25 February 2015

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

scientific article

Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era

scientific article published on 22 July 2020

Progress in acute myeloid leukemia

scientific article

Progress in the treatment of acute myeloid leukemia

scientific article published on November 2007

Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome

scientific article

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104

scientific article (publication date: 2011)

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

scientific article

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

scientific article published on 12 October 2006

Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections

scientific article

Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome

scientific article

Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia

scientific article

Proteomics-based prediction of clinical response in acute myeloid leukemia

scientific article

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

scientific article published on 19 November 2020

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

scientific article published on September 2009

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

scientific article published in January 2003

Questions regarding frontline therapy of acute myeloid leukemia

scientific article published on November 2010

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

scientific article

RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.

scientific article

RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype

scientific article published on 22 January 2015

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes

scientific article

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

scientific article published in March 2003

Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients

scientific article

Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay

scientific article

Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.

scientific article

Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts

scientific article published on 26 November 2018

Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia

Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes

scientific article published on March 2008

Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia

scientific article published on April 2013

Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment

scientific article

Relapse and death during first remission in acute myeloid leukemia

scientific article published in April 2008

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

scientific article

Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen

scientific article published in March 2004

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia

scientific article published on 27 December 2013

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia ⬇️

scientific article published on October 23, 2003

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

scientific article published on 20 April 2015

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

scientific article published on 02 December 2008

Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia

scientific article

Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

scientific article published on 01 October 2018

Reply to price and value in cancer care

scientific article published on 6 August 2015

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

scientific article

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia

scientific article published on 23 December 2008

Response kinetics and factors predicting survival in core-binding factor leukemia

scientific article published on 08 June 2018

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

scientific article

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

scientific article published on 13 March 2003

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

scientific article

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

scientific article published in March 2007

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

scientific article published on 14 October 2004

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

scientific article

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

scientific article

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

scientific article (publication date: August 2003)

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

scientific article published in April 2004

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

scientific article published in June 2003

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

scientific article published on 30 April 2013

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

scientific article

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

scientific article published on 12 April 2018

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

scientific article

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

scientific article published in September 2003

Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells

scientific article published on 10 April 2003

Retrospect of hematological malignancies 2012.

scientific article

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

scientific article

Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia

scientific article published on 16 July 2012

Revised international prognostic scoring system for myelodysplastic syndromes

scientific article

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

scientific article

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

scientific article published on 22 March 2016

Rituximab in relapsed or refractory hairy cell leukemia

scientific article

Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

scientific article

Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia

scientific article

Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on September 2011

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy

scientific article

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

scientific article published on 21 August 2017

Ruxolitinib for myelofibrosis--an update of its clinical effects

scientific article

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

scientific article

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

scientific article

SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

scientific article

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

scientific article published on 20 March 2003

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

scientific article published on 18 August 2017

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

scientific article

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

scientific article

Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia

scientific article

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

scientific article

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

scientific article

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

scientific article

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.

scientific article

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

scientific article published on 14 February 2014

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

scientific article published on 12 January 2018

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

scientific article

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

scientific article

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

scientific article

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD

scientific article

Sapacitabine for cancer

scientific article

Saving Medicare through patient-centered changes--the case of injectables

scientific article published in April 2013

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

scientific article published on 19 November 2014

Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].

scientific article published in November 2008

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

scientific article published on 09 February 2011

Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure

scientific article published on January 2009

Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome

scientific article published on 14 February 2018

Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

scientific article

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience

scientific article

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

scientific article

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Severe periorbital edema secondary to STI571 (Gleevec).

scientific article

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

scientific article published on 16 January 2013

Significance of cytogenetic abnormalities in patients with polycythemia vera

scientific article published on 17 April 2013

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

scientific article published on 12 September 2013

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

scientific article

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

scientific article published in August 2005

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

scientific article published on 4 January 2017

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

scientific article

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

scientific article

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

scientific article

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome

scientific article

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

scientific article published on 20 September 2013

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies

scientific article published on 28 September 2017

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

scientific article

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

scientific article published in November 2003

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

scientific article

Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.

scientific article

Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data

scientific article

Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells

scientific article

Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes

scientific article

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia

scientific article published on 31 August 2018

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia

scientific article published on 16 July 2019

Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation

scientific article

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

scientific article

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

scientific article published in March 2006

Standard management of patients with chronic myeloid leukemia

scientific article published on January 2009

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

scientific article published in August 2010

Strategies that delay or prevent the timely availability of affordable generic drugs in the United States

scientific article published on 27 January 2016

Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations

scientific article

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

scientific article

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes ⬇️

scientific article published on October 13, 2010

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

scientific article published on February 2009

Suboptimal responses in chronic myeloid leukemia: implications and management strategies

scientific article

Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature

scientific article published on August 2009

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation

scientific article published on 29 August 2019

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

scientific article

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

scientific article published in July 2003

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

scientific article published on December 2009

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

scientific article

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

scientific article

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

scientific article published in May 2005

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

scientific article

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

scientific article published on June 2010

Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

scientific article

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

scientific article published on 05 August 2020

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

scientific article published in July 2008

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

scientific article published in May 2009

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells

scientific article published on 29 September 2015

Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial

scientific article published on September 2009

T-cell prolymphocytic leukemia: a single-institution experience

scientific article published on 01 November 2005

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

scientific article

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

scientific article published on 8 May 2015

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

scientific article

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

scientific article published on 26 July 2016

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis

scientific article published on 30 June 2015

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

scientific article published on 24 July 2015

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation

scientific article published on 03 December 2018

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia

scientific article

Targeted therapy in chronic myeloid leukemia

scientific article published on January 2008

Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML

scientific article published on April 2016

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib

scientific article published on December 2006

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

scientific article published on 28 April 2022

Targeting DNA methylation

scientific article published on 09 June 2009

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

scientific article

Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth

scientific article published on 24 October 2013

Targeting neuropilin-1 in human leukemia and lymphoma

scientific article

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

scientific article

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia

scientific article

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia

scientific article published in July 2004

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

scientific article published on May 2015

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

scientific article published on 26 May 2010

Thalidomide therapy for myelofibrosis with myeloid metaplasia

scientific article published on 01 May 2006

The "American (cancer) patients first" plan to reduce drug prices-A critical assessment

scientific article published on 09 October 2018

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

scientific article published on 6 September 2013

The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types

scientific article published on 13 May 2020

The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015.

scientific article

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

scientific article

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

scientific article published on 27 February 2009

The Opioid Epidemic in the United States-Overview, Origins, and Potential Solutions

scientific article published on 09 October 2018

The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia

scientific article

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases.

scientific article published in October 2015

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

scientific article published on 21 November 2017

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure

scientific article

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

scientific article published on 29 July 2011

The biology and therapy of adult acute lymphoblastic leukemia ⬇️

scientific article published on October 1, 2003

The biology of chronic myelogenous leukemia: implications for imatinib therapy

scientific article published on January 2007

The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease

scientific article published in March 2002

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

scientific article published on 11 March 2013

The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia

scientific article published on October 2013

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

scientific article published on 10 August 2011

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

scientific article published in July 2005

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients

scientific article published on 13 August 2013

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

scientific article published on 30 November 2018

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

scientific article published on 19 November 2019

The effect of calcium channel blockers on the outcome of acute myeloid leukemia

scientific article

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

scientific article

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

scientific article

The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation

scientific article published on 15 January 2014

The effects of imatinib on pregnancy outcome

scientific article published on 05 March 2008

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

scientific article published on 18 March 2016

The emerging role of immune checkpoint based approaches in AML and MDS.

scientific article

The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy

scientific article published on 30 December 2015

The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.

scientific article published on 16 January 2018

The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia

scientific article published on 7 September 2010

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

scientific article

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

scientific article published on September 2016

The importance of greater speed in drug development for advanced malignancies.

scientific article published on 30 March 2018

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

scientific article published in May 2007

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

scientific article published on 19 June 2008

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

scientific article published in October 2007

The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells

scientific article published on July 2012

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

scientific article published on 29 July 2011

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

scientific article

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes

scientific article

The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients

scientific article

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

scientific article published in August 2003

The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia

scientific article published on 03 December 2012

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors

scientific article published on October 2006

The role of clofarabine in acute myeloid leukemia

scientific article

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

scientific article

The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia

scientific article published on May 2004

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

scientific article published on 8 January 2009

The role of decitabine in the treatment of myelodysplastic syndromes

scientific article published on January 2007

The role of gemtuzumab ozogamicin in acute leukaemia therapy

scientific article

The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma

scientific article published in May 2002

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on 12 March 2015

The search for better prognostic models in myelodysplastic syndromes

scientific article

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

scientific article

The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells

scientific article

The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia

scientific article

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

scientific article published on 03 September 2009

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

scientific article published on October 2008

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

scientific article

Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly

scientific article published on September 2012

Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results

scientific article published on 21 December 2012

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

scientific article

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens

scientific article

Therapy-related myelofibrosis does not appear to exist

scientific article published on 26 May 2017

Third-generation tyrosine kinase inhibitors and beyond

scientific article published on October 2010

Thrombocytopenia in patients with myelodysplastic syndromes

scientific article

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

scientific article

Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?

scientific article

Time to blur the blast boundaries

scientific article published in 2022

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

scientific article

Time-dependent changes in mortality and transformation risk in MDS.

scientific article published on 22 June 2016

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

scientific article published on 14 July 2020

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review

scientific article published on 30 April 2015

Toward the potential cure of leukemias in the next decade

scientific article published on 06 October 2018

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

scientific article

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis

scientific article published on 21 September 2020

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study

scientific article published on 21 August 2019

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

scientific article published on 19 July 2017

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

scientific article

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

scientific article published on 9 October 2003

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

scientific article published on June 2003

Treatment of acute lymphoblastic leukemia in older adults: now and the future

scientific article published on April 2017

Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies

scientific article published on September 2012

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin

scientific article

Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes

scientific article published on January 2012

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

scientific article

Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime

scientific article published on September 2003

Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options

scientific article

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

scientific article

Treatment options for chronic myeloid leukemia

scientific article published on 19 March 2012

Treatment selection after imatinib resistance in chronic myeloid leukemia

scientific article published on 30 January 2009

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

scientific article

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia

scientific article published on 04 September 2015

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

scientific article published on 26 July 2015

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.

scientific article

Trends in the management of chronic myelogenous leukemia

scientific article published in November 2005

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

scientific article published on September 2009

Troxacitabine activity in extramedullary myeloid leukemia

scientific article published in June 2002

Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation

scientific article published in March 2004

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

scientific article published on 24 April 2012

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

scientific article

Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia

scientific article

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

scientific article

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

scientific article published on 09 December 2013

Tyrosine kinase inhibitors for chronic myelogenous leukemia.

scientific article published in October 2007

Tyrosine kinase inhibitors in acute and chronic leukemias

scientific article published on May 2012

Ubiquitin–proteasome system profiling in acute leukemias and its clinical relevance ⬇️

scientific article published on October 15, 2010

Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions

scientific article published on January 2016

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

scientific article published on 31 May 2019

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

scientific article

Update: chronic myelogenous leukemia clinical practice guidelines.

scientific article published in January 2003

Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy

scientific article published in October 2002

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

scientific article

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

scientific article published in May 2003

Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm

scientific article published on 24 March 2015

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

scientific article published on 26 November 2007

Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.

scientific article

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

scientific article published on 14 December 2017

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

scientific article

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes

scientific article published on 06 December 2018

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories

scientific article published on 01 August 2018

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

scientific article published on 01 July 2006

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

scholarly article by Courtney D DiNardo et al published 25 October 2018 in Blood

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

scientific article published on 02 December 2020

Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia

scientific article published on 21 November 2014

Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

scientific article

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

scientific article published on 20 July 2017

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

scientific article published on 30 July 2015

WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells

scientific article published in December 2007

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

scientific article

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?

scientific article published on 15 June 2017

Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.

scientific article published on 6 April 2016

Why are cancer drugs so expensive in the United States, and what are the solutions?

scientific article published on 16 March 2015

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML ⬇️

scientific article published on January 1, 2011

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

scientific article

inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.

scientific article

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy

scientific article published in April 2006

Paulina is supported by:

About Paulina

Help